A new Flag­ship start­up looks to crack tR­NA bi­ol­o­gy in search for com­plete­ly new class of ther­a­peu­tics

With Mod­er­na and its mR­NA-based vac­cine act­ing as a proof of con­cept, Flag­ship Pi­o­neer­ing has dived head­first in­to tap­ping oth­er forms of RNA as po­ten­tial game chang­ers in drug de­vel­op­ment. Now, an­oth­er Flag­ship brand is off and run­ning with a first-of-its-kind pro­gram­ma­ble plat­form look­ing to un­lock the se­crets of trans­fer RNA.

All­tr­na launched Tues­day with $50 mil­lion in fund­ing from Flag­ship and years of work be­hind the scenes build­ing ex­per­tise from scratch in adapt­ing learn­ings from in­side the cell in­to a grow­ing ther­a­peu­tic plat­form based around tR­NA bi­ol­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER